13.
Rahme E, Pettitt D, LeLorier J. Determinants and sequelae
associated with utilization of acetaminophen versus traditio-
nal nonsteroidal antiinflammatory drugs in an elderly popu-
lation. Arthritis Rheum 2002;46:3046.
14.
Fored CM, Ejerblad E, Lindblad P, Fryzek JP, Dickman
PW, Signorello LB, Lipworth L, Elinder CG, Blot WJ,
McLaughlin JK, Zack MM, Nyrén O.Acetaminophen, aspi-
rin, and chronic renal failure: a nationwide case-control
study in Sweden. N Engl J Med 2001;345(25):1801-8.
15.
Forman JP, Stampfer MJ, Curhan GC. Non-narcotic analge-
sic dose and risk of incident hypertension in US women.
Hypertension 2005;46:500.
16.
Kurth T, Hennekens CH, Sturmer T, Sesso HD, Glynn RJ,
Buring JE, Gaziano JM. Analgesic use and risk of subsequ-
ent hypertension in apparently healthy men. Arch Intern
Med 2005;165:1903.
17.
Mahe I, Bertrand N, Drouet L, Simoneau G, Mazoyer E,
Baldit Sollier C, Caulin C, Bergmann JF. Paracetamol: a
haemorrhagic risk factor in patients on warfarin. Br J Clin
Pharmacol 2005;59(3):371-4.
18.
Ornetti P, Ciappuccini R, Tavernier C, Maillefert JF. Inte-
raction between paracetamol and oral anticoagulants. Rhe-
umatology (Oxford) 2005;44(12):1584-5.
19.
Hedenmalm K, Spigset O. Agranulocytosis and other blood
dyscrasias associated with dipyrone (metamizole). Eur J Clin
Pharmacol 2002;58(4):265-74.
20.
Ibáńez L, Vidal X, Ballarín E, Laporte JR. Agranulocytosis
associated with dipyrone (metamizol). Eur J Clin Pharmacol
2005;60(11):821-9.
21.
Andrade SE, Martinez C, Walker AM. Comparative safety
evaluation of non-narcotic analgesics. J Clin Epidemiol
1998;51(12):1357-65.
22.
Tulunay FC, Ergun H, Gulmez SE, Ozbenli T, Ozmenoglu
M, Boz C, Erdemoglu AK, Varlikbas A, Goksan B, Inan L.
The efficacy and safety of dipyrone (Novalgin) tablets in the
treatment of acute migraine attacks: a double-blind, cross-
over, randomized, placebo-controlled, multi-center study.
Funct Neurol 2004;19(3):197-202.
23.
Ramacciotti AS, Soares BG, Atallah AN. Dipyrone for acu-
te primary headaches. Cochrane Database Syst Rev
2007;18:(2):CD004842.
24.
Grundmann U, Wörnle C, Biedler A, Kreuer S, Wrobel M,
Wilhelm W. The efficacy of the non-opioid analgesics pare-
coxib, paracetamol and metamizol for postoperative pain re-
lief after lumbar microdiscectomy. Anesth Analg
2006;103(1):217-22.
25.
Garcia S, Canionero M, Lopes G. Dipyrone-induced granu-
locytopenia: a case for awareness. Pharmacotherapy.
2006;26(3):440-2.
26.
Clinard F, Sgro C, Bardou M, Dumas M, Hillon P, Bonit-
hon-Kopp C. Non-steroidal anti-inflammatory drug pres-
cribing patterns in general practice: comparison of a general
practitioner-based survey and a pharmacy-based survey in
France. Pharmacoepidemiol Drug Saf 2001;10:329-38.
27.
Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Var-
gas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg
MC, Kvien TK, Schnitzer TJ; VIGOR Study Group. Com-
parison of upper gastrointestinal toxicity of rofecoxib and
naproxen in patients with rheumatoid arthritis. N Engl J
Med 2000;343 (21):1520-8.
28.
Singh G, Fort JG, Goldstein JL, Levy RA, Hanrahan PS,
Bello AE, Andrade-Ortega L, Wallemark C, Agrawal NM,
Eisen GM, Stenson WF, Triadafilopoulos G; SUCCESS-I
Investigators. Celecoxib versus naproxen and diclofenac in
osteoarthritis patients: SUCCESS-I study. Am J Med
2006;119:25566.
29.
Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Do-
herty M, Ehrsam E, Gitton X, Krammer G, Mellein B,
Matchaba P, Gimona A, Hawkey CJ; TARGET Study Gro-
up. Comparison of lumiracoxib with naproxen and ibupro-
fen in the Therapeutic Arthritis Research and Gastrointes-
tinal Event Trial (TARGET), reduction in ulcer complicati-
ons: randomised controlled trial. Lancet 2004;364:665-74.
30.
Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius
B, Horgan K, Lines C, Riddell R, Morton D, Lanas A,
Konstam MA, Baron JA; Adenomatous Polyp Prevention
on Vioxx (APPROVe) Trial Investigators. Cardiovascular
events associated with rofecoxib in a colorectal adenoma
chemoprevention trial. N Engl J Med 2005;352:1092102.
31.
Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solo-
mon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle
D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner
JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR,
Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B,
Sylwestrowicz T, Gordon GB, Hawk ET; APC Study Inves-
tigators.Celecoxib for the prevention of sporadic colorectal
adenomas. N Engl J Med 2006;355:87384.
32.
Nussmeier NA, Whelton AA, Brown MT, Langford RM,
Hoeft A, Parlow JL, Boyce SW, Verburg KM. Complicati-
ons of the COX-2 inhibitors parecoxib and valdecoxib after
cardiac surgery. N Engl J Med 2005;352 (11):108191.
33.
Ott E, Nussmeier NA, Duke PC, Feneck RO, Alston RP,
Snabes MC, Hubbard RC, Hsu PH, Saidman LJ, Mangano
DT; Multicenter Study of Perioperative Ischemia (McSPI)
Research Group; Ischemia Research and Education Founda-
tion (IREF) Investigators. Efficacy and safety of the cyclo-
oxygenase 2 inhibitors parecoxib and valdecoxib in patients
undergoing coronary artery bypass surgery. J Thorac Car-
diovasc Surg 2003;125(6):148192.
34.
Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR
and Patrono C. Do selective cyclo-oxygenase-2 inhibitors
and traditional non-steroidal anti-inflammatory drugs in-
crease the risk of atherothrombosis? Meta-analysis of rando-
mised trials. BMJ 2006;332:13028.
35.
Jones R. Nonsteroidal anti-inflammatory drug prescribing:
past, present, and future. Am J Med 2001;110:4S-7S.
36.
Jack DB. One hundred years of aspirin. Lancet
1997;350:437-9.
797
BÖLÜM 52
n
Basit Analjezikler ve Steroid Olmayan Antiinflamatuvar